Summary of clinical trials with zafirlukast

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 6 II SUPPL., 1998, Pages

  Calhoun, William J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; PEPTIDOLEUKOTRIENE; PLACEBO; TERFENADINE; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR; WARFARIN; ZAFIRLUKAST;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; EXERCISE INDUCED ASTHMA; GASTRITIS; HEADACHE; HUMAN; LUNG FUNCTION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS;

EID: 0031745053     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.6.mar6     Document Type: Review

References (32)

1. National Heart, Lung, and Blood Institute. 1995. Asthma Management and Prevention: A Practical Guide for Public Health Officials and Health Care Professionals. National Institutes of Health, Bethesda, MD. Publication No. 96-3659A.
2. Goodman, D. E., E. Israel, M. Rosenberg, R. Johnston, S. T. Weiss, and J. M. Drazen. 1994. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am. J. Respir. Crit. Care Med. 150:1256-1261.
3. 4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis. 141:988-992.
4. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin. Pharmacol. Ther. 54:430-436.
5. Professional information brochure: Accolate (zafirlukast) tablets. 1997. Zeneca Pharmaceuticals. AC1107 Rev C 07/97.
6. Suttle, A. B., B. K. Birmingham, D. L. Vargo, L. A. Wilkinson, and J. Morganroth. 1997. The pharmacokinetics of zafirlukast and terfenadine after coadministration to healthy men (abstract). European Congress of Allergy and Clinical Immunology (ECACI), Rhodes, Greece, June 1-4, 1997.
7. C and area under the curve of terfenadine in healthy men (abstract). European Congress of Allergy and Clinical Immunology (ECACI), Rhodes, Greece, June 1-4, 1997.
8. Suttle, A. B., D. L. Vargo, L. A. Wilkinson, B. K. Birmingham, and K. Lasseter. 1997. Effect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men (abstract). Clin. Pharmacol. Ther. 61:186.
9. Vargo, D. L., C. Yeh, C. D. Kane, and B. K. Birmingham. 1997. Effect of zafirlukast on prothrombin time and area under the curve of warfarin (abstract). European Congress of Allergy and Clinical Immunology (ECACI), Rhodes, Greece, June 1-4, 1997.
10. Taylor, I. K., K. M. O'Shaughnessy, R. W. Fuller, and C. T. Dollery. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694.
11. Findlay, S. R., J. M. Barden, C. B. Easley, and M. Glass. 1992. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J. Allergy Clin. Immunol. 89:1040-1045.
12. Dahlén, B., O. Zetterström, T. Björck, and S.-E. Dahlén. 1994. The leukotriene-antagonist ICI-201,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen to atopic asthmatics. Eur. Respir. J. 7:324-331.
13. 4 receptor antagonist. Am. Rev. Respir. Dis. 145:746-749.
14. Israel, E., B. J. Lavins, C. J. Miller, and J. Cohn. 1996. Effect of zafirlukast on cold-air-induced bronchoconstriction in patients with bronchial asthma (abstract). Eur. Respir. J. 9(Suppl. 23):51S.
15. Boulet, L. P., T. R. Bai, C. J. Miller, B. J. Lavins, J. Cohn, H. Turcotte, and L. Atton. 1996. Effect of zafirlukast on cold-air-induced bronchoconstriction in patients with asthma (abstract). Eur. Respir. J. 9(Suppl. 23):273S.
16. 4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis. 147:215-217.
17. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am. Rev. Respir. Dis. 147:1413-1418.
18. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am. Rev. Respir. Dis. 147:1431-1435.
19. Nathan, R. A., M. Glass, and M. C. Minkwitz. 1994. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 105:483-488.
20. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma (abstract). J. Allergy Clin. Immunol. 93(1, Pt. 2):295.
21. Calhoun, W. J., K. L. Williams. S. G. Simonson, and B. J. Lavins. 1997. Effect of zafirlukast (Accolate®) on airway inflammation after segmental allergen challenge in patients with mild asthma (abstract). Am. J. Respir. Crit. Care Med. 155(Pt. 2):A662.
22. Fish, J. E., J. P. Kemp, R. F. Lockey, M. Glass, L. A. Hanby, C. M. Bonuccelli, and the Zafirlukast Trialists Group. 1997. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin. Ther. 19(4):675-690.
23. Suissa, S., R. Dennis, P. Ernst, O. Sheehy, and S. Wood-Dauphinee. 1997. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 126:177-183.
24. 4 receptor antagonist, in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 150:618-623.
25. Spector, S., C. J. Miller, and M. Glass. 1995. 13-Week dose-response study With Accolate (zafirlukast) in patients with mild to moderate asthma (abstract). Allergy 50(Suppl. 26):117.
26. Tashkin, D. P., R. A. Nathan, W. C. Howland, III, M. C. Minkwitz, and C. M. Bonuccelli. 1997. Efficacy of zafirlukast (Accolate): exploratory subset data from three 13-week multicenter trials. Am. J. Respir. Crit. Care Med. 155(Pt. 2):A663.
27. Nathan, R. A., M. Glass, and L. Snader. 1995. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) or cromolyn sodium (Intal) in patients with mild to moderate asthma (abstract). J. Allergy Clin. Immunol. 95:388.
28. Holgate, S. T., K. D. Anderson, and E. M. Rodgers. 1995. Comparison of Accolate (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients (abstract). Allergy 50(Suppl. 26):319-320.
29. Calhoun, W. J., B. J. Lavins, M. C. Minkwitz, R. Evans, G. J. Gleich, and J. Cohn. 1998. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respir. Crit. Care Med. (In press)
30. Virchow, J. C., S. M. Hassall, L. Summerton, and A. Harris. 1997. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids (abstract). J. Invest. Med. 45:286A.
31. Wechsler, M. E., E. Garpestad, S. R. Flier, O. Kocher, D. A. Weiland, A. J. Polito, M. M. Klinek, T. D. Bigby, G. A. Wong, R. A. Helmers, and J. M. Drazen. 1998. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. J.A.M.A. 279:455-457.
32. National Institutes of Health, National Heart, Lung, and Blood Institute. 1997. Highlights of the Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD.